Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Chemical aftertreatment – e.g. – acylation – methylation – etc.
Reexamination Certificate
2011-08-30
2011-08-30
Tsang, Cecilia (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Chemical aftertreatment, e.g., acylation, methylation, etc.
Reexamination Certificate
active
08008435
ABSTRACT:
A substantially hydrophilic conjugate is provided having a peptide that is capable of passing the blood-brain barrier covalently linked to a water-soluble nonpeptidic polymer such as polyethylene glycol. The conjugate exhibits improved solubility and in vivo stability and is capable of passing the blood-brain barrier of an animal.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4462941 (1984-07-01), Lee et al.
patent: 4468383 (1984-08-01), Rodbard et al.
patent: 4518711 (1985-05-01), Hruby et al.
patent: 4684624 (1987-08-01), Hosobuchi et al.
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 5017689 (1991-05-01), Hruby et al.
patent: 5286637 (1994-02-01), Veronese et al.
patent: 5326751 (1994-07-01), Haaseth et al.
patent: 5359030 (1994-10-01), Ekwuribe
patent: 5428128 (1995-06-01), Mensi-Fattohi et al.
patent: 5442043 (1995-08-01), Fukuta et al.
patent: 5629384 (1997-05-01), Veronese et al.
patent: 5631322 (1997-05-01), Veronese et al.
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5681811 (1997-10-01), Ekwuribe
patent: 5833988 (1998-11-01), Friden
patent: 5932462 (1999-08-01), Harris et al.
patent: 5948389 (1999-09-01), Stein
patent: 5990237 (1999-11-01), Bentley et al.
patent: 6024977 (2000-02-01), Yatvin et al.
patent: 6046305 (2000-04-01), Choi
patent: 6309633 (2001-10-01), Ekwuribe et al.
patent: 6362254 (2002-03-01), Harris et al.
patent: 6433135 (2002-08-01), El-Tayar et al.
patent: 6552170 (2003-04-01), Thompson et al.
patent: 6703381 (2004-03-01), Ekwuribe et al.
patent: 6899867 (2005-05-01), Bentley et al.
patent: 7056500 (2006-06-01), Bentley et al.
patent: 2002/0013266 (2002-01-01), Bentley et al.
patent: 2002/0019340 (2002-02-01), Bentley et al.
patent: 2003/0139346 (2003-07-01), Bentley et al.
patent: 2003/0144207 (2003-07-01), Bentley et al.
patent: 2004/0038899 (2004-02-01), Bentley et al.
patent: WO91/16355 (1991-10-01), None
patent: WO 91/16929 (1991-11-01), None
patent: WO 95/00162 (1995-01-01), None
patent: WO96/03984 (1996-02-01), None
patent: WO98/52415 (1998-11-01), None
patent: WO 00/78302 (2000-12-01), None
patent: WO 01/12230 (2001-02-01), None
patent: WO 01/19406 (2001-03-01), None
Inada, et al, “Modification of Proteins with Polyethylene Glycol Derivatives,” Methods in Enzymology, (1994), vol. 242, 65-90.
Delgado C, Francis GE, Fisher D., “The uses and properties of PEG-linked proteins,” Crit Rev Ther Drug Carrier Syst. 1992;9(3-4):249-304.
Wu D, Pardridge WM., “Neuroprotection with noninvasive neurotrophin delivery to the brain,” Proc Natl Acad Sci U S A Jan 5, 1999;96(1):254-9.
Delgado C, Francis GE, Fisher D., “The uses and properties of PEG-linked proteins,” Crit Rev Ther Drug Carrier Syst. 1992;9(3-4):249-304.
Wu D, Pardridge WM., “Neuroprotection with noninvasive neurotrophin delivery to the brain,” Proc Natl Acad Sci U S A. Jan 5, 1999;96(1 ):254-259.
Sakane et al., “Carboxyl-directed Pegylation of Brain-derived Neurotrophic Factor Markedly Reduces Systemic Clearance with Minimal Loss of Biological Activity,” Pharm Res., 14(8):1085-1091 (1997).
Abbruscato TJ, et al, “Blood-to-central nervous system entry and stability of biphalin, a unique double-enkephalin analog, and its halogenated derivatives,” J Pharmacol Exp Ther. Mar. 1996;276(3):1049-57.
Witt et al., “Pharmacodynamic and Pharmacokinetic Characterization of Poly(Ethylene Glycol) Conjugation of Met-Enkephalin Analog [D-Pen2, D-Pen5]-enkephalin (DPDPE),”Journal of Pharmacology and Experimental Therapeutics, vol. 298, No. 2, Aug. 2001; pp. 848-856.
Kurihara, A. et al., “Epidermal Growth Factor Radiopharmaceuticals: 111In Chelation, Conjugation to a Blood Brain Barrier Delivery Vector via a Biotin-Polyethylene Linker, . . . ”, Bioconjugate Chem., vol. 10, pp. 502-511, May 17, 1995.
Patel D. et al, “Peptide Targetting and Delivery across the Blood-Brain Barrier Utilizing Synthetic Triglyceride Esters: Design, Synthesis and Bioactivity,” Bioconjugate Chem., vol. 8, pp. 434-441 (1997).
Pardridge, “Physiologic-bases strategies for protein drug delivery to the brain,”Journal of Controlled Release, 39 pp. 281-286 (1996).
Brownlees et al., “Peptidases, Peptides, and the Mammalian Blood-Brain Barrier,”Journal of Neurochemistry, vol. 60, No. 3, pp. 793-803 (1993).
Friden, “Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier,”Journal of Controlled Release, 46, pp. 117-128 (1996).
Pardridge et al., “Combined Use of Carboxyl-Directed Protein Pegylation and Vector-Mediated Blood-Brain Barrier Drug Delivery System Optimizes Brain Uptake of Brain-Derived Neurotrophic Factor Following Intravenous Administration,”Pharmaceutical Research, vol. 15, No. 4, pp. 576-582 (1998).
Kawasaki et al., “Amino Acids and Peptides. XIX. Preparation of Enkephalin-Poly(Ethylene Glycol) Hybrid and Evaluation of Its Analgesic Activity,”Chem Pharm Bull., 41(11)pp. 2053-2054 (1993).
Maeda et al., “Amino Acids and Peptides. XXII. Preparation and Antinociceptive Effect of [D-Ala2]Leu-Enkephalin-Poly(Ethylene Glycol) Hybrid,”Chem Pharm Bull., 17(6) pp. 823-825 (1994).
Williams et al., “Passage of a δ-Opioid Receptor Selective Enkephalin, [D-Penicillamine2.5] Enkephalin, Across the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers,”J. of Neurochemistry, vol. 66, No. 3, pp. 1289-1299 (1996).
Zalipsky, “Chemistry of polyethylene glycol conjugates with biologically active molecules,”Advanced Drug Delivery Review, 16, pp. 157-182 (1995).
Zalipsky et al., “Copolymers of Lysine and Polyethylene Glycol: A New Family of Functionalized Drug Carriers,”Bioconjugate Chem., vol. 4, No. 1, pp. 54-62 (1993).
Hruby et al., “Recent Developments in the Design of Receptor Specific Opioid Peptides,”Medicinal Research Review, vol. 9, No. 3, pp. 343-401 (1989).
Non-Final rejection in U.S. Appl. No. 10/354,683, dated May 3, 2007.
Amendment by Applicant to Non-Final Rejection in U.S. Appl. No. 10/354,683 dated Jan. 23, 2007.
Non-Final Rejection in U.S. Appl. No. 10/354,683, dated Aug. 23, 2006.
Amendment by Applicant to Non-Final Rejection in U.S. Appl. No. 10/354,683, dated May 18, 2006.
Non-Final Rejection in U.S. Appl. No. 10/354,683, dated Feb. 28, 2006.
Response to Election/Restriction filed in U.S. Appl. No. 10/354,683, dated Dec. 2, 2005.
Election/Restriction filed in U.S. Appl. No. 10/354,683, dated Nov. 22, 2005.
Preliminary Amendment by Applicant for U.S. Appl. No. 10/354,683, dated Jan. 30, 2003.
The Merck Index. 11thEdition,Budavari et al. Ed, 1989 p. 1264 and p. 1379.
Sakane et al.,Pharm Res., 14(8):1085-1091 (1997).
Weber et al.,J. Pharm. Exp. Ther., 259(3):1109-1117 (1991).
Shimohigashi et al., 297:333-335 abstract (pp. 1-2) (1982).
Enzon Pharmaceuticals Catalog, “Macromolecular Engineering Technologies,” pp. 1-14 (2004).
Nektar Advanced PEGylation Catalog, “Polyethylene Glycol and Derivatives for Advanced PEGylation,” pp. 1-21 (2003).
Nektar Advanced PEGylation Catalog, “Polyethylene Glycol and Derivatives for Advanced PEGylation,” pp. 1-24 (2004).
Nektar Advanced PEGylation Catalog, “Polyethylene Glycol and Derivatives for Advanced PEGylation,” pp. 1-30 (2005-2006).
NOF Corporation Catalog, “Peg Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals,” 1: 2-46 (2003).
Polypure Products Catalog, Apr. 2005.
Quanta Biodesign Catalog, “Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG,” pp. 1-38, Mar. 12, 2004.
Quanta Biodesign Catalog, “Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG,” pp. 1-31, Nov. 5, 2004.
Quanta Biodesign Product Catalog, “Leading Innovator, Producer and Provider of Monodisperse Discrete PEG (dPEG) Derivatives,” pp. 1-
Bentley Michael David
Roberts Michael James
Evans Susan T.
Heard Thomas S
Nektar Therapeutics
Tsang Cecilia
LandOfFree
Polymer stabilized neuropeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymer stabilized neuropeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymer stabilized neuropeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2633724